Speakers

Keynote Speakers​

David Beebe picture

David Beebe
​University of Wisconsin

Moving engineered organotypic models towards the clinic

Cell-based assays for the prediction of patient-specific cancer response have not been widely adopted. However, it is timely to reevaluate their use, as numerous innovations, including micro-scale organ-on-a-chip models, may improve their predictive power and utility. We are exploring how different levels of organotypic complexity may be leveraged to recapitulate patient response in different disease states.  And the tradeoffs between the model constraints for clinical use vs. mechanistic studies.

Desai Headshot

Tejal Desai
UC  San Francisco

 

Engineering Material “Structure” to Modulate the Therapeutic Response

The ability to deliver therapeutics across biologic barriers is a much sought after goal. Here, I will recent work highlighting the impact of material structure on therapeutic delivery. Examples include nanostructured interfaces to access epithelial barriers and microstructured materials to promote local immunomodulation. By creating discrete micro and nanoscale features, one can begin to interact with cell and tissue surfaces in a manner previously unattainable. These subtle interactions can modulate properties such as permeability, matrix production, and cell activation. By gaining a better understanding of how small scale topographies can influence the biological microenvironment, these structures can be harnessed directly for therapeutic use. Micro and nanostructured materials can add functionality to current drug delivery platforms while becoming an enabling technology leading to new basic discoveries in the pharmaceutical and biological sciences.

Shana Kelley Headshot

Shana O. Kelley
University of Toronto

 

Nanoparticle-Mediated Cell Profiling: Applications in Diagnostics, Drug Development and High-Throughput Genomics

Using a high-precision approach to cell profiling, we have developed a powerful tool for the characterization of rare cells, the isolation of therapeutic cell types and capturing transient phenotypes that emerge during high-throughput screening trials.  The application of this technology to the development of liquid biopsy-based diagnostic tests and other emerging areas will be highlighted.

Butrus (Pierre) T. Khuri-Yakub

Butrus (Pierre) T. Khuri-Yakub
Stanford University

Capacitive Micromachined Ultrasonic Transducers (CMUTs): Invention to Commercialization

The capacitive micromachined ultrasonic transducer (CMUT), in its present most widely used configuration, was first published at the IEEE International Ultrasonic Symposium in 1994. The last 24 years have seen international adoption of the device, and its commercialization as a platform technology, in medical imaging and many other applications.

This presentation will start with a brief history of the invention of the CMUT and elucidate its principle of operation and merit based on basic principles. This will be followed by a discussion of the various activities necessary to realize devices: theory (analytic solution, finite element modeling); technology (sacrificial release, direct bonding); modes of operation (conventional, pull-in, permanent pull-in); electronic integration (CMUT on ASIC, flip-chip on ASIC, interposer); packaging (backing, focusing lens); and system integration.

Next, we present a few examples of using CMUTs medical imaging, and high intensity focused ultrasound therapy, and in airborne ultrasound applications such as gravimetric sensing. Finally, we will present the various entities that are presently commercializing CMUTs.